Literature DB >> 35876233

Foraging for the Optimal Dressing Scaffold to Carry Adipose-Derived Stromal/Progenitor Cells for Cell Therapy.

Chia-Chieh Wu1,2,3,4, Ying-Che Chen5, Yi-Chia Wu1,6,7, Shu-Hung Huang1,6,7, Yur-Ren Kuo1,6,7, Su-Shin Lee1,5,6,7.   

Abstract

In our daily plastic surgery practice, we have seen many chronic wounds that need new biotechnology to help and improve wound healing. Stem cells play a crucial role in regenerative medicine. Many pre-clinical researches had reported the beneficial paracrine effects of stem cell therapy for chronic wounds. Cell-friendly scaffolds may provide the protection and three-dimensional space required for adherence of stem cells, thus allowing these stem cells to proliferate and differentiate for treatment purpose. A successful scaffold may enhance the effects of stem cell therapy. In this presented series, the authors attempted to identify the most suitable scaffolds from several commercially available wound dressings that could sustain adipose-derived stromal/progenitor cells (ADSCs) survival. Therefore, we isolated ADSCs containing the green fluorescent protein (GFP) from GFP transgenic rats. The GFP (+) ADSCs and their progenies could be easily observed using a fluorescence microscope. Moreover, we analyzed the cytokines secreted in condition medium (CM) to understand the activities of ADSCs in various dressings. Our results showed that the foam dressings, hydrofiber, chitosan, and alginate plus carboxymethylcellulose were identified as the most suitable dressing materials. Higher concentrations of transforming growth factor beta (TGF-β) and vascular endothelial growth factor (VEGF) were observed 48 h after loading them with GFP (+) ADSCs. Therefore, multiple topical cell therapy using ADSCs can be performed by applying suitable dressing scaffolds without repeated needle injections to deliver the stem cells into the wound bed. Based on their fluorescence property, the GFP (+) ADSCs can also possibly be used for testing biocompatibility of medical materials in the future.

Entities:  

Keywords:  ADSCs; commercial dressing; condition medium; scaffold

Mesh:

Substances:

Year:  2022        PMID: 35876233      PMCID: PMC9326840          DOI: 10.1177/09636897221113798

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.139


Introduction

The current management of chronic wounds includes wound dressing, bedside debridement, infection control, moisture balance, and vascular assessment[1,2]. Originally, wound dressings were used to protect the wound base. With the advances made in understanding the wound-healing process, several wound dressings have been designed to maintain an optimal amount of moisture and provide an ideal environment for epithelial migration[1,2]. Numerous types of commercially available wound dressings promote wound healing. Moreover, the selection of dressings is usually based on a physician’s personal experience, availability, wound condition, cost, and patient’s preference . Zuk et al. first reported the use of adipose-derived stromal/progenitor cells (ADSCs) to improve wound healing with promising results[5-9]. ADSCs have the capacity of prolonged or unlimited self-renewal and ability to differentiate into multiple lineages . Furthermore, the paracrine effects of the ADSCs regulate the levels of cytokines around the wound site to enhance wound healing[11,12]. In the clinical setting of cell therapy, simultaneously maintaining the contact between ADSCs and the wound bed and keeping them viable are challenges that require to be solved. However, this involves repeated local injections, which makes using ADSCs in clinical practice difficult . Therefore, ADSC scaffolds have been developed as a reasonable option for chronic wound treatment. In our earlier studies[8,10], we successfully isolated ADSCs from the inguinal fatty tissue of Wistar rats. We reported the use of ADSCs to screen possible scaffold candidates from commercially available materials used during routine surgery . In this study, we explored possible wound dressing materials that can be used as scaffolds to carry ADSCs. We harvested the inguinal fatty tissue from a green fluorescent protein (GFP) transgenic SD rat and cultured ADSCs. These GFP (+) ADSCs can be traced repeatedly under a fluorescence microscope in every generation. We gathered 12 types of commercially available wound dressing materials in the clinics. The optimal scaffold had to demonstrate a high biocompatibility and be able to enhance the survival of ADSCs. We wanted to identify ADSC-friendly dressings that could serve as ADSC carriers for chronic wound cell therapy in the future.

Materials and Methods

Harvesting Adipose Tissue From GFP Transgenic Rat and Cultivating ADSCs

An SD-Tg (UBC-emGFP) 18Narl transgenic rat was purchased from the Genetic Engineering Murine Model Services, National Laboratory Animal Center (GEMMS-NLAC) in Taipei, Taiwan. The preparation procedures have been described by our colleagues Lin et al. , Lee et al. , and Sheen et al. previously. Briefly, this GFP (+) SD rat was anesthetized using an intraperitoneal injection with Zoletil 50 (50 mg/kg, Virbac Taiwan Co, Ltd, Taipei, Taiwan). Approximately 15 g subcutaneous tissue was excised from the inguinal area bilaterally. The tissue was rinsed using d-phosphate-buffered saline (d-PBS) to clean the erythrocytes. After centrifugation at 1,500 × g for 5 min, the tissue was moved to a 10-cm dish and washed. After cutting the fat tissue into small pieces, collagenase (1.5 mg/ml) was added. Then, the dish was incubated in the Dulbecco’s modified Eagle medium (DMEM) at 37°C for 20–30 min. Next, the tissues were centrifuged at 1,200× g for 5 min to remove the collagenase solution. These pellets were washed and incubated at 37°C in DMEM with 10% fetal bovine serum (FBS), 1% penicillin, 2 mM NAC, and 0.2 mM ascorbic 2-phosphate in a 5% CO2 incubator. These cells were then shifted to the keratinocyte-SFM medium the next day. The medium was changed every other day until confluence was achieved. These primary cultured cells were then collected for use by trypsinization and maintained for subculturing or stored in liquid nitrogen.

Adipogenesis Differentiation of ADSCs

Following the induction procedure reported by Lin et al. , these primary cultured cells were treated by adipogenesis supplementations in DMEM[4,13]. Oil red stain was used to monitor their successful differentiation into adipocytes.

Fluorescence-Activated Cell Sorting Analysis of ADSCs

According to the Concise Review of ADSCs written by Schaffler and Buchler , the surface markers CD90.1, CD44H, CD11b/c, CD45, and CD79α were examined. The ADSCs within the third passage were harvested and fixed in neutralized 2% paraformaldehyde solution for 30 min. These fixed cells were washed twice with PBS and incubated with antibodies against CD90.1, CD44H, CD11b/c, CD45, and CD79α for 30 min. The surface antigens of these cells were identified using flow cytometric analysis.

Seeding the ADSCs Into 12 Types of Wound Dressing Scaffolds and Synthesis of the Condition Medium

The following 12 types of wound dressings were collected in plastic surgery clinics to test their biocompatibility: Acticoat® Dressing (polyethylene mesh), AnsCare® ChitoClot Gauze (chitosan), Aquacel® foam (hydrofiber + foam), Aquacel® (hydrofiber), Aquacel® Ag (hydrofiber), Atrauman-Ag® (polyamide mesh), Biatian® Alginate Dressing [alginate + carboxymethylcellulose (CMC)], Collawound® matrix wound dressing (collagen Sponge), Mepilex Ag® (foam), PELNAC® (collagen sponge), SeaSorb Ag® (alginate + CMC), and Versiva® XC (foam). A 5-mm punch was used to cut the dressing materials and placed in a 96-well nonadhesive tissue culture plate. Keratinocyte-SFM (serum-free medium) was used to moisten these wound dressings; then, 3 × 105 GFP (+) ADSCs were loaded on each dressing material (n = 5) (Figs. 4 and 5). This culture plate was incubated at 37°C for 48 h and then the condition medium (CM) was collected for enzyme-linked immunosorbent assay (ELISA) examination to determine the concentration of three different cytokines.
Figure 4.

(A) Green fluorescent protein (GFP) (+) adipose-derived stromal/progenitor cells (ADSCs) incubated in Aquacel foam 48 h, bright field, magnification 100×, (B) fluorescent images of the same view of (A), ADSC spheres noted; (C) GFP (+) ADSCs incubated in Aquacel hydrofiber 48 h, bright field, magnification 100×, and (D) fluorescent images of the same view of (C), ADSC spheres noted.

Figure 5.

(A) Green fluorescent protein (GFP) (+) adipose-derived stromal/progenitor cells (ADSCs) incubated in Aqucel-Ag hydrofiber 48 h, bright field, magnification 100×, (B) fluorescent images of the same view of (A), ADSC spheres noted; (C) GFP (+) ADSCs incubated in Seasorb Ag 48 h, bright field, magnification 100×, and (D) fluorescent images of the same view of (C), ADSC spheres noted.

ELISA for Condition Medium

Three types of cytokines namely platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), and vascular endothelial growth factor (VEGF) were selected, as they were involved in wound healing. DuoSet ELISA development kits (R&D Systems, Minneapolis, MN, USA) were purchased. The assay was performed according to the manufacturer’s instructions. PDGF, TGF-β, and VEGF were monitored for 48 h after loading ADSCs. The TGF-β kit required a serum-free cell culture condition.

Statistical Analysis

All data values are presented as the mean values with standard deviations. Five independent experiments were performed for each wound dressing. Data were analyzed using Tukey’s test. Statistical significance was assumed at a P value of <0.05.

Results

Characterization and Verification of GFP (+) ADSCs

The cell morphology of the primary cultured cells from the SD-Tg(UBC-emGFP) 18Narl rat was assessed under a fluorescence microscope (Fig. 1). The results of adipogenesis differentiation with/without oil red stain are illustrated in Fig. 2. The flow cytometry analysis of GFP-ADSCs surface antigen, CD90.1, and CD44H were positive, whereas that of CD11b/c, CD45, and CD79α were negative. The isotype control was also negative (Fig. 3). These data proved that the primary cultured GFP (+) cells had the characteristics of ADSCs. The cumulative population doubling level (CPDL) was performed. At 24, 48, 72, 96, and 120 h, the level of proliferation are 140%, 320%, 660%, 1,450%, and 2,330%, respectively (supporting data).
Figure 1.

(A) Morphology of green fluorescent protein (+) adipose-derived stromal/progenitor cells (ADSCs) from subcutaneous fat pads cultured in vitro, (B) bright field, (C) fluorescent images of ADSCs, magnification: 40×, and (D) fluorescent images, magnification: 100×.

Figure 2.

Multilineage differentiation—adipogenesis, green fluorescent protein (GFP) (+) adipose-derived stromal/progenitor cells (ADSCs) Under Oil Red Stain, (A) GFP (+) ADSCs control, magnification: 100×, (B) GFP (+) ADSCs control, magnification: 200×, (C) GFP (+) ADSCs post induction, magnification: 100×, and (D) GFP (+) ADSCs post induction, magnification: 200×.

Figure 3.

Flow cytometry analysis of green fluorescent protein (GFP)-adipose-derived stromal/progenitor cell (ADSC) surface antigens. CD90.1 and CD44H were positive, whereas CD11b/c, CD45, and CD79α were negative, and the isotype control was also negative.

(A) Morphology of green fluorescent protein (+) adipose-derived stromal/progenitor cells (ADSCs) from subcutaneous fat pads cultured in vitro, (B) bright field, (C) fluorescent images of ADSCs, magnification: 40×, and (D) fluorescent images, magnification: 100×. Multilineage differentiation—adipogenesis, green fluorescent protein (GFP) (+) adipose-derived stromal/progenitor cells (ADSCs) Under Oil Red Stain, (A) GFP (+) ADSCs control, magnification: 100×, (B) GFP (+) ADSCs control, magnification: 200×, (C) GFP (+) ADSCs post induction, magnification: 100×, and (D) GFP (+) ADSCs post induction, magnification: 200×. Flow cytometry analysis of green fluorescent protein (GFP)-adipose-derived stromal/progenitor cell (ADSC) surface antigens. CD90.1 and CD44H were positive, whereas CD11b/c, CD45, and CD79α were negative, and the isotype control was also negative.

Images of GFP (+) ADSCs Incubated in the 12 Dressing Materials at 48 h

The fluorescence microscope was used to assess these dressing materials. The GFP (+) ADSCs could be seen in some of the images. In some dressing, the ADSCs gathered together to become “spheres” (Figs. 4 and 5). However, these images did not represent the entire amount of ADSCs on the dressing materials. They provided information only on the qualitative analysis. (A) Green fluorescent protein (GFP) (+) adipose-derived stromal/progenitor cells (ADSCs) incubated in Aquacel foam 48 h, bright field, magnification 100×, (B) fluorescent images of the same view of (A), ADSC spheres noted; (C) GFP (+) ADSCs incubated in Aquacel hydrofiber 48 h, bright field, magnification 100×, and (D) fluorescent images of the same view of (C), ADSC spheres noted. (A) Green fluorescent protein (GFP) (+) adipose-derived stromal/progenitor cells (ADSCs) incubated in Aqucel-Ag hydrofiber 48 h, bright field, magnification 100×, (B) fluorescent images of the same view of (A), ADSC spheres noted; (C) GFP (+) ADSCs incubated in Seasorb Ag 48 h, bright field, magnification 100×, and (D) fluorescent images of the same view of (C), ADSC spheres noted.

Cytokine Concentration in the CM

ADSCs secrete various cytokines. To understand the quantities of ADSCs and their responses when implanted on various scaffolds, the culture media that were used for these GFP (+) ADSCs in daily care were collected. These media were checked for PDGF-αβ, TGF-β1, and VEGF. However, no difference was noted in the concentrations of PDGF-αβ among these CMs (Table 1). Significantly high concentrations of TGF-β1 and VEGF were noted in the foam dressing, chitosan dressing, hydrofiber, and alginate plus CMC groups (Tables 2 and 3).
Table 1.

The Level of PDGF-αβ Secreted From GFP (+) ADSC in Different Medical Materials.

PDGF-αβ (pg/ml)Mean ± SDRange
ControlK-medium only2.1 ± 1.30.08–3.34
Ag (−)Versiva XC (foam)5.0 ± 0.74.03–5.66
PELNAC (collagen sponge)4.6 ± 1.72.17–5.90
Aquacel foam (hydrofiber + foam)4.3 ± 1.62.17–6.13
Collawound (collagen Sponge)4.3 ± 1.02.87–5.20
Biatian Alginate (alginate + CMC)3.9 ± 1.52.41–6.13
Aquacel (hydrofiber)3.2 ± 0.92.17–4.27
AnsCare (chitosan)3.0 ± 1.31.71–4.97
Ag (+)Seasorb Ag (alginate + CMC)5.3 ± 1.64.03–7.52
Mepilex Ag (foam)4.0 ± 1.92.17–6.59
Atrauman Ag (polyamide mesh)3.3 ± 1.71.24–5.20
Aquacel Ag (hydrofiber)3.1 ± 1.91.01–5.43
Acticoat (polyethylene mesh)3.0 ± 0.91.71–4.03

Groups not sharing a same letter (a, b, c, d, e) are significantly different and group sharing (*) are significantly different by Tukey’s test (P < 0.05) (n = 5). ADSC: adipose-derived stromal/progenitor cell; CMC: carboxymethylcellulose; GFP: green fluorescent protein; PDGF: platelet-derived growth factor.

Table 2.

The Level of TGF-β1 Secreted From GFP (+) ADSC in Different Medical Materials.

TGF-β1 (pg/ml)Mean ± SDRange
ControlK-medium only0.7 ± 0.70.00–1.43 d
Ag (−)Versiva XC (foam)36.1 ± 8.4*25.71–47.14 a
Aquacel foam (hydrofiber + foam)35.3 ± 6.4*28.57–45.71 a
AnsCare (chitosan)32.6 ± 8.2*21.43–40.00 a b
Aquacel (hydrofiber)29.6 ± 8.3*17.86–39.29 a b
Biatian alginate (alginate + CMC)24.1 ± 9.7*12.14–37.86 a b c
Collawound (collagen sponge)19.7 ± 4.9*13.57–25.71 b c
PELNAC (collagen sponge)12.9 ± 2.710.00–17.14 c d
Ag (+)Aquacel Ag (hydrofiber)25.6 ± 8.8*15.71–37.86 a b c
Seasorb Ag (alginate + CMC)25.4 ± 9.9*14.29–39.29 a b c
Mepilex Ag (foam)6.3 ± 4.10.71–11.42 d
Acticoat (polyethylene mesh)5.9 ± 4.41.43–12.86 d
Atrauman Ag (polyamide mesh)5.9 ± 5.20.71–13.57 d

Groups not sharing a same letter (a, b, c, d) are significantly different and group sharing (*) are significantly different by Tukey’s test (P < 0.05) (n = 5). ADSC: adipose-derived stromal/progenitor cell; CMC: carboxymethylcellulose; GFP: green fluorescent protein; TGF-β: transforming growth factor beta.

Table 3.

The Level of VEGF Secreted From GFP (+) ADSCs in Different Medical Materials.

VEGFMean ± SDRange
K-medium only5.0 ± 4.40–8.75e
Ag (−)Versiva XC (foam)128.5 ± 12.8*112.50–146.25 a
Aquacel foam (hydrofiber + foam)123.3 ± 15.3*101.25–143.75 a b
Aquacel (hydrofiber)122.8 ± 14.9*102.50–141.25 a b
AnsCare (chitosan)118.3 ± 12.4*105.00–135.00 a b
Biatian Alginate (alginate + CMC)90.0 ± 9.8*78.75–103.75 c
Collawound (collagen Sponge)83.0 ± 6.0*75.00–90.00 c
PELNAC (collagen sponge)50.5 ± 13.4*35.00–71.25 d
Ag(+)Seasorb Ag (alginate + CMC)103.3 ± 7.7*91.25–110.00 b c
Aquacel Ag (hydrofiber)88.5 ± 12.0*71.25–100.00 c
Mepilex Ag (foam)27.3 ± 12.416.25–47.50e
Atrauman Ag (polyamide mesh)27.0 ± 10.315.00–41.25e
Acticoat (polyethylene mesh)26.5 ± 11.917.50–46.25e

Groups not sharing a same letter (a, b, c, d) are significantly different and group sharing (*) are significantly different by Tukey’s test (P < 0.05) (n = 5). ADSC: adipose-derived stromal/progenitor cell; CMC: carboxymethylcellulose; GFP: green fluorescent protein; VEGF: vascular endothelial growth factor.

The Level of PDGF-αβ Secreted From GFP (+) ADSC in Different Medical Materials. Groups not sharing a same letter (a, b, c, d, e) are significantly different and group sharing (*) are significantly different by Tukey’s test (P < 0.05) (n = 5). ADSC: adipose-derived stromal/progenitor cell; CMC: carboxymethylcellulose; GFP: green fluorescent protein; PDGF: platelet-derived growth factor. The Level of TGF-β1 Secreted From GFP (+) ADSC in Different Medical Materials. Groups not sharing a same letter (a, b, c, d) are significantly different and group sharing (*) are significantly different by Tukey’s test (P < 0.05) (n = 5). ADSC: adipose-derived stromal/progenitor cell; CMC: carboxymethylcellulose; GFP: green fluorescent protein; TGF-β: transforming growth factor beta. The Level of VEGF Secreted From GFP (+) ADSCs in Different Medical Materials. Groups not sharing a same letter (a, b, c, d) are significantly different and group sharing (*) are significantly different by Tukey’s test (P < 0.05) (n = 5). ADSC: adipose-derived stromal/progenitor cell; CMC: carboxymethylcellulose; GFP: green fluorescent protein; VEGF: vascular endothelial growth factor.

Discussion

The wound-healing process is highly regulated by secretion of various growth factors, cytokines, and chemokines . Chronic wounds require an extended healing period because their endogenous healing mechanisms are disrupted. With technological advancements, administration of exogenous growth factors has shown promise in stimulating chronic wound healing . However, the cost of recombinant human growth factors is high, and proper conservation to maintain their bioactivities is an uncertain issue. Cell therapy has recently gained attention because it provides new hope for patients who have not experienced successful wound healing by conventional treatments . Different cells (fibroblasts, keratinocytes, platelets, ADSCs) have been used to convert the wound bed into an environment where maximum wound healing can be achieved . ADSCs were evaluated for regenerative application because these cells are easy to isolate, relatively abundant, and multipotent . The stem cells’ therapeutic potential is largely due to their capability to secrete pro-regenerative cytokines, causing them to be an attractive choice for the treatment of chronic wounds . ADSCs can promote wound healing and trigger neovascularization through their ability to differentiate endothelial cells and release VEGF . The ADSCs could differentiate within the epithelium or secrete several types of cytokines (paracrine effect) that stimulated angiogenesis to improve wound healing[7,8,19,21]. Tremolada et al. reported a novel Lipogems® technology which helped to enhance the healing of lower leg chronic ulceration, especially in diabetic patients. The exosome content has been demonstrated to be significantly greater in fat tissue processed with Lipogems® than with the enzymatic method. The Lipogems® system yields a microfragmented autologous adipose tissue that acts as a large-scale tool to supply damaged tissues with a regenerative environment in a one-step intervention . This method can activate the natural healing process without using enzymes, additives, or separation centrifugation and relying instead on mild mechanical forces . ADSCs are extremely promising as an alternative tool for the regenerative strategy for wound therapy . Kallmeyer et al. reported local injections of ADSCs for rat wound model cell therapy. Their ADSCs were transduced to express both GFP and firefly luciferase to enable tracking by immune-histological analysis and bioluminescence imaging. They found that these local injected ADSCs could become distributed within the wound bed in 24 h. And these ADSCs were strongly detectable up to 7 days. In our earlier animal studies , the authors had reported ADSC injections for the animal chronic wound model cell therapy. However, merely applying the ADSCs over the wound surface would be less invasive. Topical coverage with ADSCs might make it easier for the institutional review board to approve our human clinical trial in the future. Therefore, identification of suitable scaffolds that could carry as many ADSCs as possible should be explored in future research. Clinical physicians are not specialized in chemical synthesis and are unable to create new scaffold materials. Commercially available dressings might reduce the concerns of biotoxicity from new chemical synthetic materials. Hence, we tested several commercially available wound dressings to evaluate their potential as ADSC carrier scaffolds and examine their biocompatibility. In this present series, we harvested the adipose tissue from the GFP (+) transgenic SD rat to isolate GFP (+) ADSCs. Moreover, the surface antigens of our primary cultured cell lines were CD90.1(+) and CD44H(+), whereas CD11b/c, CD45, and CD79α were all negative as observed using flow cytometry analysis . We have proven that our primary culture cell lines possess the characteristics of stem cells[10,13]. GFP (+) ADSCs were used to serve as a biocompatibility testing tool. In this study, we identified the most cell-friendly commercial wound dressings and sought potential scaffold candidates that could serve as ADSC carriers during cell therapy for difficult wounds. Because each generation of GFP (+) ADSCs could be observed under a fluorescence microscope, we could trace the positions of GFP (+) ADSCs repeatedly. However, these wound dressings were not transparent. We also detected fluorescence in some of the dressing materials under the fluorescence microscope. Fluorescence microscope observations could be considered only as a “qualitative analysis.” We were unable to identify which dressing material was superior using only fluorescence microscope findings. The ADSCs that survived within the scaffolds would be able to secrete various cytokines. The amount of cytokine secretion is proportional to the survived number of ADSCs. Therefore, the cytokine levels in the CM were studied. The ADSCs can emanate a variety of cytokines, and several studies have reported on the ADSC-CM[12,25-27]. The ADSCs promote proliferation of dermal fibroblasts by using not only cell-to-cell contact but also paracrine cytokines . In this series, we collected and analyzed the CMs from 3 × 105 GFP (+) ADSCs in different commercially available dressing materials. We measured the concentrations of PDGF, TGF-β1, and VEGF by using the ELISA technique because these three cytokines were crucial growth factors that might improve wound healing. From the viewpoint of cell therapy, a better scaffold should possess a higher concentration of these cytokines in their CMs. In clinical practice, the chronic wounds shall be inspected and changed dressing daily or every other day to prevent wound infection. The old dressing will be removed and discarded. A new dressing will be applied to the wound. So, in the clinical cell therapy “ADSCs carrying dressing” may cover the wound only for 24 to 48 h. Then, another new ADSCs carrying dressing will replace the old one. Therefore, in this study, we evaluate the cytokine levels from the 48 h of ADSC dressings’ CM. Our results revealed no significant differences in PDGF levels (Table 1). However, obvious variations were noted in the concentrations of TGF-β1 and VEGF in different dressing materials (Tables 2 and 3). In general, dressing materials with nanosilver particles were less cell-friendly in comparison with dressings without these particles. Moreover, the dressings with high concentrations of TGF-β1 (>30 pg/ml) were Versiva® XC (foam), Aquacel® foam (hydrofiber + foam), and AnsCare® (chitosan). Also, Versiva® XC (foam), Aquacel® foam (hydrofiber +foam), Aquacel® (hydrofiber), AnsCare® (chitosan), and SeaSorb Ag® (alginate + CMC) demonstrated high concentrations of VEGF (>100 pg/ml).

Limitation

Our study has several limitations. First, the GFP (+) cells can only be seen in the transparent scaffold. The non-transparency and some unknown fluorescent material in the dressings make our observation difficult. Second, the ADSCs may survive on the dressing longer than 48 h. However, this study design did not investigate the pattern or growth of ADSCs on the dressing longer than 48 h. Further research may be needed to study the longevity of ADSCs on these dressing. Third, in clinical situation, some ADSCs may translocate to the wound bed. This study did not provide information about this issue. Further analyses and investigations are suggested.

Conclusion

In summary, we successfully isolated GFP (+) ADSCs from the GFP (+) transgenic SD rat. The adipogenesis differentiation and sorting of surface antigen cells proved that these primary cultured cell lines had the characteristics of stem cells. The GFP (+) ADSCs were then used to test 12 types of commercially available wound dressings. We identified three types of dressings with TGF-β1 concentrations of >30 pg/ml in the CM and five types of dressings with VEGF concentrations of >100 pg/ml in the CM. VEGF and TGF-β1 are growth factors vital for wound healing. This study demonstrated that we can select appropriate scaffold dressings for autologous ADSCs seeding to perform cell therapy in human patients with chronic wounds. Moreover, based on their fluorescence property, the GFP (+) ADSCs can possibly be used for testing biocompatibility of medical materials in the future. Click here for additional data file. Supplemental material, sj-jpg-2-cll-10.1177_09636897221113798 for Foraging for the Optimal Dressing Scaffold to Carry Adipose-Derived Stromal/Progenitor Cells for Cell Therapy by Chia-Chieh Wu, Ying-Che Chen, Yi-Chia Wu, Shu-Hung Huang, Yur-Ren Kuo and Su-Shin Lee in Cell Transplantation Click here for additional data file. Supplemental material, sj-pptx-1-cll-10.1177_09636897221113798 for Foraging for the Optimal Dressing Scaffold to Carry Adipose-Derived Stromal/Progenitor Cells for Cell Therapy by Chia-Chieh Wu, Ying-Che Chen, Yi-Chia Wu, Shu-Hung Huang, Yur-Ren Kuo and Su-Shin Lee in Cell Transplantation
  27 in total

Review 1.  Advanced Therapeutic Dressings for Effective Wound Healing--A Review.

Authors:  Joshua Boateng; Ovidio Catanzano
Journal:  J Pharm Sci       Date:  2015-08-26       Impact factor: 3.534

Review 2.  Choosing a Wound Dressing Based on Common Wound Characteristics.

Authors:  Ganary Dabiri; Elizabeth Damstetter; Tania Phillips
Journal:  Adv Wound Care (New Rochelle)       Date:  2016-01-01       Impact factor: 4.730

Review 3.  Concise review: adipose tissue-derived stromal cells--basic and clinical implications for novel cell-based therapies.

Authors:  Andreas Schäffler; Christa Büchler
Journal:  Stem Cells       Date:  2007-04       Impact factor: 6.277

4.  Human adipose tissue is a source of multipotent stem cells.

Authors:  Patricia A Zuk; Min Zhu; Peter Ashjian; Daniel A De Ugarte; Jerry I Huang; Hiroshi Mizuno; Zeni C Alfonso; John K Fraser; Prosper Benhaim; Marc H Hedrick
Journal:  Mol Biol Cell       Date:  2002-12       Impact factor: 4.138

Review 5.  Chronic Wounds: Evaluation and Management.

Authors:  Steven Bowers; Eginia Franco
Journal:  Am Fam Physician       Date:  2020-02-01       Impact factor: 3.292

6.  Human Adipose-Derived Mesenchymal Stem Cells in Cell Therapy: Safety and Feasibility in Different "Hospital Exemption" Clinical Applications.

Authors:  Sophie Vériter; Wivine André; Najima Aouassar; Hélène Antoine Poirel; Aurore Lafosse; Pierre-Louis Docquier; Denis Dufrane
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

7.  Autologous and not allogeneic adipose-derived stem cells improve acute burn wound healing.

Authors:  Yu-Wei Chang; Yi-Chia Wu; Shu-Hung Huang; Hui-Min David Wang; Yur-Ren Kuo; Su-Shin Lee
Journal:  PLoS One       Date:  2018-05-22       Impact factor: 3.240

8.  The relative contribution of paracine effect versus direct differentiation on adipose-derived stem cell transplantation mediated cardiac repair.

Authors:  Dezhong Yang; Wei Wang; Liangpeng Li; Yulan Peng; Peng Chen; Haiyun Huang; Yanli Guo; Xuewei Xia; Yuanyuan Wang; Hongyong Wang; Wei Eric Wang; Chunyu Zeng
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

9.  Mesenchymal stem cells in tissue repairing and regeneration: Progress and future.

Authors:  Jiafei Xi; Xinlong Yan; Junnian Zhou; Wen Yue; Xuetao Pei
Journal:  Burns Trauma       Date:  2013-06-18

10.  Higher Pericyte Content and Secretory Activity of Microfragmented Human Adipose Tissue Compared to Enzymatically Derived Stromal Vascular Fraction.

Authors:  Bianca Vezzani; Isaac Shaw; Hanna Lesme; Li Yong; Nusrat Khan; Carlo Tremolada; Bruno Péault
Journal:  Stem Cells Transl Med       Date:  2018-09-26       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.